Skip to main content Accessibility help
×
Home
Hostname: page-component-768ffcd9cc-9th95 Total loading time: 0.188 Render date: 2022-11-29T22:50:09.585Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "displayNetworkTab": true, "displayNetworkMapGraph": false, "useSa": true } hasContentIssue true

An Open-Label Trial of Aripiprazole Monotherapy in Children and Adolescents with Bipolar Disorder

Published online by Cambridge University Press:  07 November 2014

Abstract

Introduction: Aripiprazole is a novel second-generation antipsychotic approved for the treatment of bipolar disorder in adults but there is no systematic data available in pediatric bipolar disorder.

Methods: This was an 8-week, open-label, prospective study of aripiprazole 9.4±4.2 mg/day monotherapy to assess the efficacy and tolerability of this compound in treating pediatric bipolar disorder. Assessments included the Young Mania Rating Scale, Clinical Global Impressions-Improvement scale, and Brief Psychiatric Rating Scale. Adverse events were assessed through spontaneous self-reports, vital signs weight monitoring, and laboratory analysis.

Results: Fifteen of the 19 bipolar youth (79%) completed the study. Aripiprazole treatment was associated with clinically and statistically significant improvement in mean Young Mania Rating Scale scores (−18.0±6.9, P<.0001). With the important exception of two cases of extrapyramidal symptoms that precipitated dropout, aripiprazole was well tolerated with no statistically significant increase in body weight (1.8±1.7 kg, P=.2).

Conclusion: Open-label aripiprazole treatment was beneficial in the treatment of mania in youth with bipolar disorder. Future placebo-controlled, double blind studies are warranted.

Type
Original Research
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Tohen, M, Ketter, TA, Zarate, CA, et al.Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003;160:12631271.CrossRefGoogle ScholarPubMed
2.Keck, PE Jr, Versiani, M, Potkin, S, et al.Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160:741748.CrossRefGoogle ScholarPubMed
3.Perlis, RH, Welge, JA, Vornik, LA, Hirschfeld, RM, Keck, PE Jr.Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2006;67:509516.CrossRefGoogle ScholarPubMed
4.Frazier, JA, Biederman, J, Tohen, M, et al.A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2001;11:239250.CrossRefGoogle ScholarPubMed
5.Biederman, J, Mick, E, Wozniak, J, Aleardi, M, Spencer, T, Faraone, SV. An open-label trial of risperidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2005;15:311317.CrossRefGoogle ScholarPubMed
6.Biederman, J, Mick, E, Hammerness, P, et al.Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry. 2005;58:589594.CrossRefGoogle ScholarPubMed
7.DelBello, MP, Kowatch, RA, Adler, CM, et al.A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2006;45:305313.CrossRefGoogle ScholarPubMed
8.Biederman, J, McDonnell, MA, Wozniak, J, et al.Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectr. 2005;10:141148.CrossRefGoogle ScholarPubMed
9.Barzman, DH, Delbello, MP, Kowatch, RA, et al.The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. J Child Adolesc Psychopharmacol. 2004;14:593600.CrossRefGoogle ScholarPubMed
10.Gibson, AP, Crismon, ML, Mican, LM, Fischer, C. Effectiveness and tolerability of aripiprazole in child and adolescent inpatients: a retrospective evaluation. Int Clin Psychopharmacol. 2007;22:101105.CrossRefGoogle ScholarPubMed
11.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
12.Fristad, MA, Weller, RA, Weller, EB. The Mania Rating Scale (MRS): further reliability and validity studies with children. Ann Clin Psychiatry. 1995;7:127132.CrossRefGoogle ScholarPubMed
13.Fristad, MA, Weller, EB, Weller, RA. The Mania Rating Scale: can it be used in children? A preliminary report. J Am Acad Child Adolesc Psychiatry. 1992;31:252257.CrossRefGoogle ScholarPubMed
14.Young, R, Biggs, J, Ziegler, V, Meyer, D. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429435.CrossRefGoogle ScholarPubMed
15.Youngstrom, EA, Danielson, CK, Findling, RL, Gracious, BL, Calabrese, JR. Factor structure of the Young Mania Rating Scale for use with youths ages 5 to 17 years. J Clin Child Adolesc Psychol. 2002;31:567572.CrossRefGoogle Scholar
16.Lachar, D, Bailley, SE, Rhoades, HM, et al.New subscales for an anchored version of the Brief Psychiatric Rating Scale: construction, reliability, and validity in acute psychiatric admissions. Psychol Assess. 2001;13:384395.CrossRefGoogle ScholarPubMed
17.National Institute of Mental Health. CGI (Clinical Global Impression) Scale. Psychopharmacol Bull. 1985;21:839844.Google Scholar
18.Keck, PJ, Marcus, R, Tourkodimitris, S, et al.A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160:16511658.CrossRefGoogle ScholarPubMed
19.Tohen, M, Zarate, CA Jr, Centorrino, F, Hegarty, JI, Froeschl, M, Zarate, SB. Risperidone in the treatment of mania. J Clin Psychiatry. 1996;57:249253.Google ScholarPubMed
20.Wozniak, J, Biederman, J, Kiely, K, et al.Mania-like symptoms suggestive of childhood-onset bipolar disorder in clinically referred children. J Am Acad Child Adolesc Psychiatry. 1995;34:867876.CrossRefGoogle ScholarPubMed
21.Armenteros, J, Whitaker, A, Welikson, M, Stedge, D, Gorman, J. Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry. 1997;36:694700.CrossRefGoogle Scholar
22.McDougle, CJ, Holmes, JP, Bronson, MR, et al.Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry. 1997;36:685693.CrossRefGoogle ScholarPubMed
23.Quintana, U, Keshavan, M. Case study: risperidone in children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 1995;34:12921296.CrossRefGoogle ScholarPubMed
47
Cited by

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

An Open-Label Trial of Aripiprazole Monotherapy in Children and Adolescents with Bipolar Disorder
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

An Open-Label Trial of Aripiprazole Monotherapy in Children and Adolescents with Bipolar Disorder
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

An Open-Label Trial of Aripiprazole Monotherapy in Children and Adolescents with Bipolar Disorder
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *